Will BridgeBio's Attruby net product revenue exceed $175M in Q1 2026?

Q4 2025 revenue was $146M with 35% QoQ growth. $175M represents ~20% QoQ growth — a meaningful deceleration but still strong. The second prescriber wave (1,856 prescribers, accelerating adoption) and strong persistency provide demand momentum. The committee confirmed OPERATIONAL_EXECUTION = EXCEEDING. However, the disclosure reduction on patient starts introduces uncertainty about demand trajectory, and Q1 typically has seasonal softness in new starts. The $175M threshold is achievable but not certain.

Revenue trajectory math: Q3=$108M, Q4=$146M (35% QoQ). At 20% QoQ, Q1=$175M exactly. But launch curves typically show deceleration — the 35% QoQ pace is unlikely to sustain. Historical rare disease launches show QoQ growth rates of 15-25% in the second year of launch. With 7,804 cumulative patients and ~$46K/patient annual revenue, reaching $175M requires roughly 15,200 cumulative patients (assuming mix of full-quarter and partial-quarter revenue). This is an increase of ~1,900 patients in Q1. Management's strong persistency claims suggest low churn, so gross-to-net patient additions of 2,000-2,500 could be needed.

The committee rated OPERATIONAL_EXECUTION as EXCEEDING with HIGH confidence — the strongest positive signal in the entire analysis. Revenue has beaten expectations every quarter since launch. The second prescriber adoption wave is atypical for specialty launches and suggests organic clinical conviction rather than promotional pull-through. Attruby's clinical differentiation (near-complete TTR stabilization) and FDA's Alnylam warning letter create favorable competitive dynamics. The $175M threshold asks only for 20% QoQ when the trailing rate is 35%. Even with significant deceleration, crossing $175M is more likely than not.

The revenue trajectory is strong but launch curves decelerate. The 35% QoQ rate in Q4 benefited from the second prescriber wave — a one-time inflection that won't repeat at the same magnitude. Q1 seasonal effects (New Year, insurance resets, prior authorization delays) typically slow new starts. The $175M threshold is achievable given the existing patient base and persistency, but it's not a slam dunk. Management stopping patient start disclosures adds uncertainty — if the number were clearly positive, why hide it?

The recurring revenue base is the strongest argument. With 7,804 patients at ~$46K/year, the existing cohort generates approximately $90M/quarter. Q4's $146M means new patient revenue contributed ~$56M. Even if new patient additions decline 30% from Q4 pace, the recurring base plus reduced new additions should push past $175M. Revenue is partially subscription-like in rare disease — persistency matters more than new starts once the base is established.

Declining Google Trends for 'Attruby' is a concerning signal that Sonnet flagged — it may indicate peak awareness/interest passing. However, specialist pharma launches are physician-driven, not consumer search-driven, so Google Trends may be a poor proxy for actual prescribing behavior. The key risk is that the second prescriber wave was a one-time catch-up rather than sustained organic adoption. If prescriber growth plateaus, patient additions slow, and the 20% QoQ target becomes harder to achieve.

Strong launch trajectory with 35% QoQ growth. Second prescriber wave supports continued momentum. $175M requires only 20% QoQ growth — significant deceleration buffer. Existing patient base provides recurring revenue floor. Probability weighted toward YES given execution track record.

Launch curve deceleration is expected in year two. Q1 seasonal effects add headwind. But the 20% QoQ threshold provides substantial room for deceleration from 35%. Revenue has exceeded expectations every quarter. More likely than not to cross $175M but not high confidence.

The recurring revenue base argument is compelling — 7,804 patients at $46K/year means ~$90M/quarter just from existing patients. Getting to $175M requires ~$85M from continuing patients plus new additions. Even if new patient growth slows significantly, the math works for $175M unless there is unexpected churn. Persistency data described as 'exceeding expectations' supports this.